Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugssierra health and life Spravato/Ketalar Coverage U…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0069P

    Ketalar (Ketamine) and Spravato (Esketamine) coverage

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0069P alerts

    Get alerted when Policy 2026D0069P changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coverage criteria for Spravato (esketamine) nasal spray for treatment-resistant depression and MDD with acute suicidal ideation/behavior; describes coverage and investigational stances for ketamine injection and documents REMS-based administration and prior authorization requirements affecting providers.

    Policy Summary
    Payersierra health and life
    PolicyKetalar (Ketamine) and Spravato (Esketamine) coverage
    Policy CodePolicy 2026D0069P
    Change TypeHCPCS code update (J0013 addedS0013 removed)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of diagnosis, at least two failed antidepressant trials (≥8 weeks each), REMS certification of provider/setting, and required assessment scores.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Updated list of applicable HCPCS codes to reflect annual edits: Added J0013 and Removed S0013.

    2antidepressant trials required for TRD
    12 monthsmax authorization period
    J0013, J3490HCPCS codes listed
    4RCTs in meta-analysis
    708total patients (meta-analysis)
    2HCPCS edits (added/removed)

    Coverage Criteria

    Initial Therapy - TRD

    Spravato (esketamine) for treatment-resistant depression (TRD) is covered when ALL of the following are met:

    Diagnosis of major depressive disorder (treatment-resistant) according to the current DSM by a mental health professional
    Prior treatment failures: History of failure of at least two different antidepressants or treatment regimens with documentation of medication, date, and durationeach trial ≥ 8 weeks

    Acceptable regimens include SSRIs, SNRIs, bupropion, TCAs, mirtazapine, MAOIs, serotonin modulators, or augmentation strategies (antipsychotics, lithium, thyroid hormone)

    REMS certification: Provider and/or the provider's healthcare setting is certified in the Spravato REMS program
    Prescriber: Prescribed by or in consultation with a psychiatrist
    Dosing: Spravato dosing is in accordance with United States FDA approved labeling
    Authorization period: Initial authorization will be for no longer than 12 months12 months

    Continuation of Therapy - TRD

    Continuation (reauthorization) criteria for Spravato (TRD):

    Clinical response: Documentation of remission or a positive clinical response to Spravato therapy

    Must include recent assessment within the last month

    Assessment scores: Submission of baseline and recent (within the last month) scores on BDI, HAMD, MADRS, PHQ-9, or QIDS demonstrating remission or score reductionrecent within last month
    REMS and prescriber: Provider/setting REMS certified and prescribed by or in consultation with a psychiatrist
    Dosing and authorization period: Dosing per FDA approved labeling; reauthorization will be for no longer than 12 months

    Initial Therapy - MDD with acute suicidal ideation or behavior

    Spravato for MDD with acute suicidal ideation or behavior is covered when ALL of the following are met:

    Diagnosis of major depressive disorder according to the current DSM by a mental health professional
    Acute suicidality: Patient is experiencing acute suicidal ideation or behavior
    Concomitant antidepressant: Patient will receive Spravato in conjunction with a newly initiated or optimized oral antidepressant

    Per trial protocols and FDA labeling

    REMS and dosing: Provider/setting REMS certified and dosing per FDA approved labeling
    Authorization period:

    Ketamine injection - covered and investigational uses

    Ketamine injection coverage stance:

    Covered uses: Medically necessary for anesthesia for diagnostic and surgical procedures that do not require skeletal muscle relaxation; induction of anesthesia prior to other agents; supplemental anesthesia for low-potency agents (e.g., nitrous oxide)
    Not covered uses: Investigational and not medically necessary for psychiatric disorders (including depression, bipolar disorder, PTSD), chronic pain (including fibromyalgia, neuropathic pain, CRPS), and migraine headaches

    Clinical evidence and REMS-based administration constraints

    Evidence summary and contexts where esketamine demonstrated benefit in trials

    Esketamine demonstrated efficacy in:: Short-term trials (e.g., TRANSFORM-2) showed statistically significant improvement in MADRS versus placebo; SUSTAIN-1 randomized withdrawal showed longer time to relapse when continuing esketamine; ASPIRE I and II showed superiority on MADRS at 24 hours in adults with MDD and active suicidal ideation when added to standard of care; Popova et al showed greater MADRS improvement at day 28 when switching to esketamine plus a newly initiated antidepressant versus newly initiated antidepressant plus placebo.

    Effect sizes and time-course vary by study; some short-term trials did not meet primary endpoints.

    Safety and program requirements: Spravato is available only through a REMS; it must be dispensed and administered in certified healthcare settings with direct observation and at least 2 hours of post-dose monitoring due to risks including sedation, dissociation, and potential for abuse/misuse.

    Spravato and ketamine are not supported for certain uses outside their approved indications. Spravato is unproven and not medically necessary when used as an anesthetic agent, for chronic pain (including fibromyalgia, neuropathic pain, complex regional pain syndrome/Reflex Sympathetic Dystrophy), and for migraine headaches. Ketamine injection is considered investigational and not medically necessary for psychiatric disorders (including but not limited to depression, bipolar disorder, and PTSD), chronic pain conditions, and migraine headaches.

    Spravato is not approved as an anesthetic agent; its safety and effectiveness as an anesthetic have not been established. In addition, compounded ketamine products (including oral formulations) have been the subject of a recent FDA warning identifying potential risks when used for treatment of psychiatric disorders. Providers and payers should note the lack of approval and the FDA advisory when evaluating requests for non‑labeled uses.

    The FDA has issued a public warning about potential risks associated with compounded ketamine products, including oral formulations, for treatment of psychiatric disorders. This advisory underscores safety concerns and supports caution or exclusion of such compounded formulations for psychiatric indications in coverage determinations.

    Spravato is considered unproven and not medically necessary when proposed as an anesthetic agent or for chronic pain and migraine. Ketamine injection retains an approved role for anesthesia (induction and supplementation) but is investigational and not medically necessary for psychiatric disorders, chronic pain conditions, and migraine. Coverage for esketamine is limited to its labeled psychiatric indications and subject to REMS program requirements.

    Evidence for ketamine use in bipolar depression and as an adjunct to electroconvulsive therapy is limited and rated as low or insufficient quality by technology assessments. Reviews conclude that single‑dose intravenous ketamine may produce a rapid but transient antidepressant effect, while repeated infusions show greater and more durable effects; overall, Hayes assigned ratings such as C (potential but unproven benefit) or D2 (insufficient evidence) for these uses, indicating the evidence does not support routine coverage.

    Initial Therapy Requirements

    Initial therapy - Spravato

    Initial authorization requirements for Spravato

    Diagnosis: Major depressive disorder (treatment-resistant) or MDD with acute suicidal ideation/behavior

    Diagnosis per current DSM by a mental health professional

    Prior therapy (TRD only): Failure of at least two different antidepressants or treatment regimens documented (medication, date, and duration) each ≥ 8 weeks≥ 2 trials, ≥ 8 weeks each

    Includes listed classes and augmentation strategies

    REMS: Provider/setting certified in Spravato REMS program

    Continuation / Reauthorization

    Spravato continuation therapy

    Reauthorization requirements for Spravato

    Clinical response evidence: Documentation of remission or positive clinical response with submission of baseline and recent assessment scores (BDI, HAMD, MADRS, PHQ-9, QIDS) demonstrating improvementrecent within last month

    Reauthorization will be for no longer than 12 months

    Continuation therapy evidence

    Randomized withdrawal (SUSTAIN-1) findings on continuation

    Continuation benefit: Patients who achieved ≥ 50% reduction in MADRS after 4 weeks of open-label esketamine plus oral antidepressant and entered optimization had statistically significant longer time to relapse if randomized to continue esketamine versus switch to placebo (both with oral antidepressant ongoing)≥ 50% MADRS reduction

    Coding and Diagnosis Codes

    Applicable HCPCS and ICD-10 codesmixed
    J0013Esketamine, nasal spray, 1 mg
    J3490Unclassified drugs
    F33.0Major depressive disorder, recurrent, mild
    F33.1Major depressive disorder, recurrent, moderate
    F33.2Major depressive disorder, recurrent severe without psychotic features
    F33.3Major depressive disorder, recurrent, severe with psychotic symptoms
    F33.40Major depressive disorder, recurrent, in remission, unspecified
    F33.41Major depressive disorder, recurrent, in partial remission
    F33.42Major depressive disorder, recurrent, in full remission
    F33.8Other recurrent depressive disorders
    1–10 of 11
    1/2
    Applicable HCPCS Codes - editsHCPCS
    J0013Added (applicable HCPCS code)
    S0013Removed (formerly applicable HCPCS code)
    Antidepressant trial duration — policy vs. phase 3 trials
    Policy-required trial durationEach prior antidepressant trial must be at least 8 weeks in duration per policy
    Phase 3 trials definitionPhase 3 studies defined an adequate trial as ≥6 weeks for the purposes of trial inclusion
    Documentation requiredDocument medication name, start/end dates, and duration for each prior trial

    Provider Actions & Documentation

    Prior Authorization

    Prior Authorization & Documentation Required

    Prior authorization is required for Spravato (esketamine) nasal spray. Submit documentation of diagnosis, prior antidepressant treatment failures (medication name, dates, duration), baseline depression assessment scores, and evidence that the prescribing provider and administration site are certified in the Spravato REMS program. Initial and reauthorization approvals are limited to no longer than 12 months.

    • Prior authorization required for Spravato for TRD
    • Document history of failure of at least two different antidepressants or regimens (each ≥ 8 weeks) including medication name, start/end dates, and duration
    • Provide baseline scoring on an approved depression assessment (BDI, HAMD, MADRS, PHQ-9, QIDS) prior to starting Spravato
    Documentation Required

    REMS Certification & Administration Requirements

    Spravato must be dispensed and administered only in REMS-certified healthcare settings with patients enrolled in the Spravato REMS program. Administration must be performed under direct observation and the patient monitored for at least 2 hours after dosing. Coverage reviewers should verify REMS enrollment and that the provider/site certification is current.

    Site of Care & Administration Settings

    Prior Authorization

    Ensure REMS certification of provider/setting

    Providers and healthcare settings must be certified in the Spravato REMS program to administer Spravato; ensure site certification is current before scheduling treatment.

    • Certification of the administering healthcare setting in the Spravato REMS is required
    • Only REMS‑certified settings may dispense and administer Spravato
    Documentation Required

    Administer Spravato in certified setting with direct observation and ≥2‑hour monitoring

    Dispense and administer Spravato only in REMS‑certified settings with direct observation of dosing and at least 2 hours of post‑dose monitoring; document these site‑of‑care processes in the patient record.

    • Direct observation of dosing by a healthcare provider is required
    • Record at least 2 hours of monitoring following each administration

    Definitions

    Treatment-resistant depression (TRD) — definition
    Policy definition (short)Failure to have a clinically meaningful improvement after at least two different antidepressant agents prescribed at adequate dose and duration
    Clinical population notePatients who have failed at least two trials generally comprise TRD; definition is not fully standardized
    Phase 3 trial thresholdIn phase 3 studies, treatment resistance was defined as ≤25% improvement after ≥6 weeks on ≥2 antidepressants
    Esketamine / Spravato — description and indications
    Drug identity and mechanismSpravato (esketamine) is the S‑enantiomer of racemic ketamine and a non-competitive NMDA receptor antagonist
    IndicationsIndicated for treatment-resistant depression (TRD) in adults and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior (in conjunction with an oral antidepressant)

    Step Therapy

    RequirementDetails
    Failure of prior antidepressant trials
    History of failure of a trial of at least two different antidepressants or treatment regimens
    Minimum duration per trial
    Each trial must be for a duration of at least 8 weeks (document medication, date, and duration)
    Accepted classes/regimens
    Includes SSRIs, SNRIs, bupropion, tricyclics, mirtazapine, MAOIs, serotonin modulators, or augmentation strategies (antipsychotics, lithium, thyroid hormone)
    StatementNotes
    No explicit step-therapy algorithm in policy excerpt
    The document does not specify a mandated sequencing algorithm; trials enrolled patients with prior inadequate response (e.g., Popova et al required retrospective nonresponse to 1–5 antidepressants)
    Clinical-trial contexts commonly required prior inadequate response
    Meta-analysis and trials evaluated adjunctive or switched-to esketamine in patients with prior nonresponse; benefit seen as early as 2–24 hours and up to 28 days in RCTs

    Background

    Major depressive disorder (MDD) is common and can be severe; a substantial minority of patients—approximately 30–40%—fail first‑line treatments and may meet criteria for treatment‑resistant depression (TRD). TRD is generally defined in this policy as failure to achieve clinically meaningful improvement after at least two different antidepressant trials given at adequate dose and duration, and esketamine (Spravato) is indicated for TRD and for depressive symptoms with acute suicidal ideation or behavior when used per FDA labeling and REMS requirements.

    Policy Summary
    Payersierra health and life
    PolicyKetalar (Ketamine) and Spravato (Esketamine) coverage
    Policy CodePolicy 2026D0069P
    Change TypeHCPCS code update (J0013 addedS0013 removed)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of diagnosis, at least two failed antidepressant trials (≥8 weeks each), REMS certification of provider/setting, and required assessment scores.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy RequirementsContinuation / ReauthorizationCoding and Diagnosis CodesProvider Actions & DocumentationSite of Care & Administration SettingsDefinitionsStep TherapyBackground
    12 months
    Initial authorization will be for no longer than 12 months
    12 months
    Concomitant antidepressant (suicidality indication): Spravato given with newly initiated or optimized oral antidepressant for the acute suicidal ideation/behavior indication

    Per ASPIRE trial design and FDA labeling

    Dosing consistent with United States FDA approved labeling
    Authorization duration: Initial authorization no longer than 12 months12 months

    Initial therapy contexts

    Trial contexts for initiation

    Esketamine initiation context: In clinical trials, esketamine was used either as monotherapy after discontinuation of prior antidepressants or adjunctive to a newly initiated oral antidepressant for TRD; trial entry commonly required documented nonresponse to prior antidepressants.

    The excerpt does not specify an alternate required prior-treatment failure count beyond policy criteria.

    Supports benefit of continued esketamine in those who responded initially

    • Patient must be enrolled in the Spravato REMS program prior to administration
    • Administration only in REMS-certified healthcare setting
    • Patient monitored ≥ 2 hours post-dose; documentation of monitoring must be submitted
    Documentation Required

    REMS Documentation (What to Submit)

    Document REMS-related evidence in the medical record: proof of patient enrollment in Spravato REMS, facility or provider REMS certification, and notes showing direct observation and post-dose monitoring. Failure to meet REMS requirements may result in denial of coverage.

    • Attach REMS enrollment confirmation for the patient
    • Attach provider/setting REMS certification documentation
    • Include nursing/observation notes showing direct observation and monitoring duration
    Documentation Required

    Prior Antidepressant Trial Documentation

    Ensure prior antidepressant trial documentation shows failure of at least two different antidepressants or regimens (each ≥ 8 weeks). Include agent/class, dose, dates, reason for discontinuation (lack of efficacy, intolerance), and any augmentation strategies tried.

    • List each antidepressant or regimen with start and end dates and duration (≥ 8 weeks each)
    • State the reason for treatment failure for each trial (nonresponse, adverse effects, etc.)
    • Include trials across classes when applicable (SSRI, SNRI, bupropion, TCA, MAOI, mirtazapine, augmentation with antipsychotic/lithium/thyroid)
    Note

    Clinical Trial Context for Sequencing

    Clinical trial evidence supports use of esketamine as adjunctive therapy to a newly initiated oral antidepressant and as monotherapy in TRD. When documenting sequencing, note whether Spravato is being used adjunctively with a newly started oral antidepressant or as monotherapy and include supporting clinical rationale.

    • If used adjunctively, document initiation of the concurrent oral antidepressant and timing relative to Spravato dosing
    • If used as monotherapy, document discontinuation of prior antidepressants if applicable and rationale for monotherapy use
    • Reference supportive trial endpoints (e.g., MADRS score change at day 28) when relevant
    Note

    Reference Member-Specific Benefit Plan

    Before applying this policy, always check the member-specific benefit plan document and any applicable federal or state mandates. In case of conflict, the member specific benefit plan governs. Coverage reviewers and providers should verify member-specific coverage rules and benefit limits.

    • Refer to the member specific benefit plan for coverage determinations
    • Confirm any applicable state or federal mandates that may affect coverage
    • When in conflict, follow the member specific benefit plan document
    Billing Rule

    Updated Applicable HCPCS Codes

    Applicable HCPCS/administrative coding for prior authorization and claims has been updated. Use the payer’s current applicable code list when submitting requests and claims to ensure accurate processing.

    • Updated HCPCS: J0013 added
    • Removed HCPCS: S0013
    • Verify payer-specific code list before submission
    Note

    Use of External Criteria Tools

    This policy may be used alongside third-party utilization management tools (e.g., InterQual) to assist in administering health benefits. Providers should follow any additional documentation or criteria required by those tools or by the payer’s reviewer.

    • InterQual or other third-party criteria may be applied in conjunction with this policy
    • Follow additional documentation requests from payer reviewers or external criteria tools
    Note

    Follow member plan and mandates for site‑of‑care decisions

    Follow the member specific benefit plan and applicable mandates when interpreting this informational policy; site‑of‑care rules in the member plan may supersede the guidance here.

    • This policy is informational and may apply to Medical Benefit Drug coverage in some plans
    • Adhere to member‑specific site‑of‑care requirements and federal/state mandates
    Not an anestheticSpravato is not approved as an anesthetic agent; safety/effectiveness as an anesthetic not established
    REMS — Spravato restricted program and requirements
    Program name and purposeSpravato REMS (Risk Evaluation and Mitigation Strategy) — restricted program due to risks of sedation, dissociation, and abuse/misuse
    Setting certificationHealthcare settings must be certified in the REMS and may only dispense/administer Spravato to enrolled patients
    Monitoring requirementPatients must be directly observed during dosing and monitored for at least 2 hours after administration
    MADRS — role in esketamine trials
    Assessment instrumentMADRS (Montgomery‑Åsberg Depression Rating Scale) used as the primary efficacy endpoint in esketamine phase 3 trials
    Administration and scoringMADRS is a clinician-rated scale with evaluations performed by independent, blinded raters assessing symptoms over the prior 7 days
    Baseline severity in trialsBaseline mean MADRS total scores in phase 3 studies ranged ~35–38, indicating moderate-to-severe illness